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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
CranMax® and reduction of the risk of urinary tract infection by inhibiting 
the adhesion of certain bacteria in the urinary tract pursuant to Article 14 
of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Jemo-pharm A/S, submitted pursuant to Article 14 of Regulation (EC) 
No 1924/2006 via the Competent Authority of Denmark, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to CranMax® 
and reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary 
tract. The food that is the subject of the claim is CranMax®. The Panel considers that the food, CranMax®, 
which is the subject of the claim is sufficiently characterised in relation to the claimed effect. The Panel 
considers that reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the 
urinary tract is a beneficial physiological effect. One human study from which conclusions could be drawn for 
the scientific substantiation of the claim did not show an effect of CranMax® on reduction of the risk of urinary 
tract infection by inhibiting the adhesion of certain bacteria in the urinary tract. The Panel concludes that a cause 
and effect relationship has not been established between the consumption of CranMax® and reduction of the risk 
of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Jemo-pharm A/S, submitted pursuant to Article 14 of Regulation (EC) 
No 1924/2006 via the Competent Authority of Denmark, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to CranMax® and reduction of the risk of urinary tract infection (UTI) by inhibiting the 
adhesion of certain bacteria in the urinary tract. 
The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction. The application includes a request for the protection of proprietary data. 
The food that is the subject of the health claim is CranMax®, which contains cranberry (Vaccinium 
macrocarpon) powder obtained from the whole fruit and seeds. The product is marketed in the form of 
capsules. The applicant indicated that the product is standardised for proanthocyanidins (PAC) 
content. The Panel considers that the food, CranMax®, which is the subject of the health claim is 
sufficiently characterised in relation to the claimed effect. 
The claimed effect proposed by the applicant is ―prevents adhesion of E. coli to the uroepithelial cells 
in women, which is a risk factor for developing urinary tract infections (UTI)‖. The target population 
proposed by the applicant is ―women from 18 years complaining of recurrent UTI‖. The Panel 
considers that the health claim refers to reduction of the risk of UTI by inhibiting the adhesion of 
certain bacteria in the urinary tract in healthy women without signs or symptoms of UTI and does not 
include the treatment of UTI. The Panel considers that reduction of the risk of UTI by inhibiting the 
adhesion of certain bacteria in the urinary tract is a beneficial physiological effect. 
The applicant identified four human intervention studies, two in vitro studies and one review paper as 
pertinent to the claim. 
The Panel considers that the one human study from which conclusions could be drawn for the 
scientific substantiation of the claim did not show an effect of CranMax® on reduction of the risk of 
UTI by inhibiting the adhesion of certain bacteria in the urinary tract. 
Two in vitro studies and one narrative  review paper addressed inhibition of adherence of Escherichia 
coli to the uroepithelial cells cultures in the presence of cranberry juice or PAC. The Panel considers 
that these studies do not provide evidence that inhibition of the adhesion of E. coli to uroepithelial 
cells demonstrated in vitro predicts the occurrence of a clinically relevant inhibition of the adhesion of 
certain bacteria to uroepithelial cells in humans. 
The only human study from which conclusions could be drawn for the scientific substantiation of the 
claim did not show an effect of CranMax® on reduction of the risk of UTI by inhibiting the adhesion 
of certain bacteria in the urinary tract. On the basis of the data presented, the Panel concludes that a 
cause and effect relationship has not been established between the consumption of CranMax® and 
reduction of the risk of UTI by inhibiting the adhesion of certain bacteria in the urinary tract. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of permitted 
claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 03/07/2013. 
 The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction. 
 The scientific evaluation procedure started on 24/09/2013. 
 On 22/11/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the clock 
was stopped on 04/12/2013, in compliance with Art. 18(3) of Regulation (EC) No 1924/2006. 
 On 24/02/2014, EFSA received the requested information as submitted by the applicant and 
the clock was restarted. 
 During its meeting on 10/04/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to CranMax® and 
reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in 
the urinary tract. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to CranMax® and reduction of the risk of 
urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of procyanidins in cranberry, a positive assessment of its safety, nor a decision on whether CranMax® 
is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
CranMax® and reduction of the risk of urinary tract infection  
 
 
6 EFSA Journal 2014;12(5):3657 
INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Jemo-pharm A/S, Hasselvej 1, 4780 Stege, Denmark. 
Food as stated by the applicant 
According to the applicant, the food for which this health claim is made is CranMax®—cranberry 
extract. One capsule contains 170–200 mg anthocyanins. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is the prevention of the adhesion of E. coli to 
uroepithelial cells, which is a risk factor for developing UTIs. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wordings for the health claim: ―Prevent adhesion of E. coli 
to the uroepithelial cells in women which is a risk factor for developing urinary tract infections‖. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of 500–1000 mg per day of CranMax® cranberry extract. It can 
be administrated as 500 mg once a day or 250 mg twice a day or 500 mg twice a day. The target 
population proposed is women aged 18 years and over complaining of recurrent UTI. 
ASSESSMENT 
1. Characterisation of the food 
The applicant stated that the food that is the subject of the health claim is CranMax®, which contains 
cranberry (Vaccinium macrocarpon) powder (500 mg) obtained from the whole fruit and seeds. The 
product is marketed in the form of capsules (capsule weight 623 mg). 
The applicant indicated that the product is standardised for proanthocyanidins (PAC) content. PACs 
constitute a group of flavan-3-ols ranging from dimers to polymers. There are differences in the 
linkages (A- or B-type) between the monomeric units. The content of PACs in the product is measured 
by UV absorbance at 545 nm after acid hydrolysis and extraction in butanol. The PAC content is 
specified as ≥ 7.2 % (at least 36 mg in one capsule). The total phenols content of the product is also 
given. 
Information about the manufacturing process (the cranberry pulp is dried and milled), the stability and 
the batch-to-batch variability was provided. 
The Panel considers that the food, CranMax®, which is the subject of the health claim is sufficiently 
characterised in relation to the claimed effect. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is ―prevents adhesion of E. coli to the uroepithelial cells 
in women which is a risk factor of developing urinary tract infections (UTI)‖. The target population 
proposed by the applicant is ―women from 18 years complaining from recurrent UTI‖. 
Bacterial adherence to mucosal surfaces is facilitated by fimbriae, which are proteinaceous fibres on 
the bacterial cell wall (Duguid et al., 1955; Beachey, 1981). Preventing adhesion facilitates urinary 
flushing of the bacteria, thereby preventing bacterial colonisation of the urinary tract (Foo et al., 
2000). 
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The Panel considers that the health claim refers to reduction of the risk of UTI by inhibiting the 
adhesion of certain bacteria in the urinary tract in healthy women without signs or symptoms of UTI 
and does not include the treatment of UTI. 
The Panel considers that reduction of the risk of UTI by inhibiting the adhesion of certain bacteria in 
the urinary tract is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
A Medline, Cochrane Library, EMBASE and Google engines were used in a literature search without 
language restrictions looking for clinical studies on CranMax® used for prevention of UTIs in women 
with recurrent UTIs. The decision tree used in the search process was not presented. The Panel notes 
that the search strategy was inadequately described. 
The applicant identified four human intervention studies, two in vitro studies and one review paper as 
pertinent to the claim. 
Stothers (2002) evaluated the effectiveness of CranMax® in the prevention of UTIs in women in a 
randomised, placebo-controlled, three-arm study. Subjects with at least two symptomatic UTIs in the 
prior calendar year, but currently free of UTI (150 women aged 21–72 years, mean 42 years), were 
randomised to ingest CranMax® 500 mg/day or cranberry juice (3  250 mL, containing the same 
amount of PACs), or placebo for 12 months (n = 50 subjects in each group). The endpoints measured 
were a 50 % decrease in symptomatic UTIs per year (UTI defined as the presence of symptoms and 
≥ 105 bacteria/mL in urine culture) and > 50 % decrease in annual antibiotic consumption. The cost-
effectiveness of the use of cranberry products was also calculated as a primary outcome. A total of 127 
women finished the study (40 subjects in the tablet group, 44 in the juice group and 43 in placebo 
group). The Panel notes that this publication reported insufficient information on the settings of the 
study, on the criteria used for UTI diagnosis, on the statistical methods applied and on the procedures 
used for urine analysis for scientific evaluation, and no clarification was provided by the applicant in 
response to a request by EFSA. The Panel considers that no conclusions can be drawn from this study 
for the scientific substantiation of the claim. 
Bohbot (2007) studied the effect of two cranberry products on the incidence of UTI in sexually active 
female subjects with recurrent urinary infections. In this randomised, double-blind, three-arm study, 
women who had had at least three episodes of UTI over the preceding six months and who had sexual 
intercourse on more than one occasion every two weeks were included. For 45 days following 
inclusion, the subjects were advised to take one capsule of either cranberry product with a brand name 
GynDelta® (claimed by the applicant as identical to CranMax®) or an extract of cranberry containing 
36 mg of PAC A or a placebo within six hours after sexual intercourse. The number of recurring 
episodes of UTI, time to recurrence of UTI symptoms and product tolerability were evaluated as 
primary outcomes. Out of the 120 subjects entered into the trial, a total of 111 women (37 in each 
group) finished the study. The per protocol method was used in the statistical analysis of the results. 
The Panel notes that the diagnosis of UTI was based only on self-reported symptoms collected at the 
end of the study and it was not confirmed by urine analysis. The Panel also notes that there was no 
information on the management of the symptoms, in particular whether antibiotics were used, no 
information about the total amounts of the intervention product and placebo consumed over the entire 
study period in each group, and no clarification was provided by the applicant in response to an EFSA 
request for additional information. The Panel considers that no conclusions can be drawn from this 
study for the scientific substantiation of the claim. 
In a parallel, double-blind study, McMurdo et al. (2009) compared the effectiveness of PAC product 
(CranMax®) with low-dose trimethoprim (TMT) in the prevention of recurrent UTI in a population of 
women aged > 45 years with at least two episodes of antibiotic-treated UTIs or cystitis in the previous 
12 months. Participants (n = 137) were randomised to receive either one capsule of CranMax® 
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(n = 69, mean age 62.6 ± 10.8 years) or 100 mg of TMT (n = 68, mean age 63.3 ± 10.1 years) taken at 
bedtime for six months. The primary endpoints were the recurrence rate of an antibiotic-treated UTI 
and the time to first recurrence. There were 17 (12 %) withdrawals from the study (six in the 
CranMax® group and 11 in TMT group). Statistical analysis was claimed to be intention to treat (ITT) 
analysis. The Panel notes that in reality the statistical analysis was conducted per protocol, as the 
comparison between groups did not take the missing data into account. The Panel also notes that the 
study was underpowered to detect differences between groups (post hoc power is much lower than 
specified in the methods; n = 168 per group should be randomised to reach power = 80 %). The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim. 
In a similar study, Beerepoot et al. (2011) compared the effect of cranberry product (CranMax®) with 
trimethophrim–sulphamethoxazole (TMT-SMX) in the prevention of UTIs in premenopausal women 
with recurrent UTIs. The study was carried out in a group of women (n = 221) with a medical history 
of at least three self-reported symptomatic UTIs in the year preceding enrolment but free of symptoms 
at the time of enrolment. They were randomised to 12 months of ingestion of one tablet containing 
480 mg TMT-SMX at night and one placebo capsule twice daily (n = 110, median age 36.1 years) or 
one CranMax® capsule twice daily and one placebo tablet at night (n = 111, median age 34.8 years). 
The primary outcomes were the mean number of symptomatic UTIs over 12 months, the proportion of 
patients with at least one symptomatic UTI, and the median time to the first symptomatic UTI. UTI 
was defined on the basis of a woman’s subjective report of clinical symptoms, usually dysuria, 
frequency and/or urgency. Mean number of microbiologically confirmed UTIs, the percentage of 
patients with at least one recurrence and the median time to first microbiologically confirmed UTI 
constituted the secondary outcomes. A total of 110 participants (50 %) finished the study giving 53 
who completed in the cranberry group and 57 in the TMT-SMX group. The statistical analysis was 
carried out to establish the non-inferiority of cranberry powder intake compared with TMT-SMX 
prophylaxis. Power calculation was performed accordingly. Analyses were completed by the use of 
inverse probability-of-censoring weighting, in order to correct for informative censoring. The mean 
number of clinical UTIs was 1.8 (95 % confidence interval (CI) 0.8–2.7) in the TMT-SMX group and 
4.0 (95 % CI 2.3–5.6) in the cranberry group and the between-group difference after 12 months was 
outside the non-inferiority margin. The proportion of patients with at least one symptomatic UTI was 
higher in the CranMax® group (78.2 % vs. 71.1 %, p = 0.03) than in the control group. The median 
time to first recurrence was eight months for the TMT-SMX and four months for the cranberry group 
(p = 0.03). Secondary outcomes were not statistically different. The Panel notes that the number of 
drop-outs was large and no information was provided about handling of missing data, and that 
majority of comparisons were performed using inverse probability-of-censoring weighting, a 
technique which is likely to provide biased outcome estimates in the face of a small sample size and 
strong selection bias. The Panel notes that this study with several limitations showed that CranMax® 
was inferior to antibacterial therapy in the prevention of UTIs in premenopausal women with recurrent 
UTIs. 
The applicant also submitted two in vitro studies and one review paper on the inhibition of adherence 
of E. coli to the culture of uroepithelial cells in the presence of cranberry juice or PAC (Zafriri et al., 
1989; Howell et al., 1998; Lavigne et al., 2007). The Panel notes that several health claim applications 
on cranberry products standardised by their PAC content and in which inhibition of the adhesion of E. 
coli to uroepithelial cells by the urine of subjects consuming cranberry products was demonstrated, 
have already been evaluated by EFSA (EFSA, 2009; EFSA NDA Panel, 2011, 2013a, b). The studies 
provided in these applications did not establish that inhibition of the adhesion of E. coli to 
uroepithelial cells demonstrated in vitro or ex vivo predicts the occurrence of a clinically relevant 
inhibition of the adhesion of certain bacteria to uroepithelial cells in humans. 
In weighing the evidence, the Panel considers that one human study from which conclusions could be 
drawn for the scientific substantiation of the claim did not show an effect of CranMax® on reduction 
of the risk of UTI by inhibiting the adhesion of certain bacteria in the urinary tract. 
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On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of CranMax® and reduction of the risk of UTI by 
inhibiting the adhesion of certain bacteria in the urinary tract. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, CranMax®, which is the subject of the health claim is sufficiently characterised in 
relation to the claimed effect. 
 The claimed effect is ―prevention of adhesion of E. coli to uroepithelial cells which is a risk 
factor for developing urinary tract infections‖. The target population as proposed by the 
applicant is healthy women complaining of recurrent UTI. Reduction of the risk of UTI by 
inhibiting the adhesion of certain bacteria in the urinary tract is a beneficial physiological 
effect. 
 A cause and effect relationship has not been established between the consumption of 
CranMax® and reduction of the risk of UTI by inhibiting the adhesion of certain bacteria in 
the urinary tract. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on CranMax® and reduction of the risk of UTIs by inhibiting the adhesion of 
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